Sutro Biopharma, Inc.
Clinical trials sponsored by Sutro Biopharma, Inc., explained in plain language.
-
New combo drug trial for Tough-to-Treat ovarian cancer halted
Disease control TerminatedThis early-stage trial tested the safety and best dose of a new drug, STRO-002, when given with an existing cancer drug, bevacizumab. It was for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that had come back or stopped responding to standard treatme…
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New hope for women battling Tough-to-Treat ovarian cancer?
Disease control TerminatedThis study tested an experimental drug called luveltamab tazevibulin against standard chemotherapy for women with advanced ovarian cancer that had returned and stopped responding to platinum-based drugs. It aimed to see if the new drug could better control the cancer and improve …
Phase: PHASE2, PHASE3 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC